复发和转移性头颈癌的免疫治疗与生物标志物检测:ASCO指南
ASCO召集多学科专家组,检索2000至2022年文献,纳入28项相关研究,制定复发和转移性头颈癌免疫治疗与生物标志物检测的循证推荐。推荐涉及PD-L1评分指导的一线方案、铂类难治性复发/转移性头颈鳞癌的免疫治疗、鼻咽癌免疫治疗及放疗联合免疫治疗局部复发。
要点
- PD-L1评分可用于指导复发/转移性头颈鳞癌的一线免疫治疗方案选择。
- 铂类难治性复发/转移性头颈鳞癌可考虑免疫治疗。
- 鼻咽癌及局部复发病灶的免疫治疗与放疗联合应用需遵循指南推荐。
英文原文(摘要)· 点击展开
PURPOSE: To provide evidence-based recommendations for practicing physicians and other health care providers on immunotherapy and biomarker testing for head and neck cancers.
METHODS: ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, radiology, pathology, and patient advocacy experts to conduct a literature search, including systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2022. Outcomes of interest included survival, overall response, and locoregional control. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations.
RESULTS: The literature search identified 28 relevant studies to inform the evidence base for this guideline.
RECOMMENDATIONS: When possible, evidence-based recommendations were developed to address biomarker testing, first-line treatment regimens based on programmed death ligand-1 scores, immunotherapy in platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma, immunotherapy in nasopharyngeal carcinoma, and radiation therapy in combination with immunotherapy for treatment of local recurrence.Additional information is available at www.asco.org/head-neck-cancer-guidelines.
引用
- Yilmaz, Ismaila, Bauman, et al. Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. J Clin Oncol. 2022. PMID: 36521102. doi:10.1200/JCO.22.02328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。